Laboratory Studies Confirm the Effectiveness of BETADINE® Gargle and Mouthwash Against COVID-19 Virus
30.6.2020 17:57:00 EEST | Business Wire | Press release
Laboratory testing completed at the Tropical Infectious Diseases Research and Education Center (TIDREC) at the University of Malaya, Malaysia, has confirmed the effectiveness of BETADINE® Gargle and Mouthwash against the novel coronavirus (SARS-CoV-2) which causes COVID-19 disease. BETADINE® is manufactured and distributed in Malaysia by Mundipharma.
BETADINE® Gargle and Mouthwash was tested for virucidal activity in two concentrations, undiluted (PVP-I 1% w/v) and at a 1:2 dilution (PVP-I 0.5% w/v) under established European (EN14476) methodology and standards. The testing demonstrated strong in-vitro virucidal activity, with the tested products killing 99.99% of the SARS-CoV-2 virus in just 15 seconds.
The TIDREC research has been accepted by the British Dental Journal (BDJ) and was published as a Letter on 26 June 2020. The journal is published by Springer Nature on behalf of the British Dental Association.
“Laboratory testing has shown that BETADINE® Gargle and Mouthwash is effective against COVID-19 and could contribute to our ongoing efforts to keep people and communities safe,” said Dr Pouya Hassandarvish, the Lead Investigator of the Study and the postdoctoral fellow researcher at TIDREC, University of Malaya.
“These results confirm our view that BETADINE® Gargle and Mouthwash, used appropriately and in conjunction with other preventative treatment options including PPE, could play a role in limiting the spread of infections, including COVID-19,” said Raman Singh, Mundipharma CEO.
“It also provides the medical and dental community with a science-based assurance that they are using a product that is specifically studied against COVID-19,” he added.
Previously, BETADINE® antiseptic products containing Povidone-iodine (PVP-I) have been proven effective against a wide range of viruses, including coronaviruses that have caused major outbreaks such as Middle East Respiratory Syndrome (MERS) and Severe Acute Respiratory Syndrome (SARS). The BETADINE® antiseptic range contains Povidone-iodine (PVP-I), which is effective against a wide range of microorganisms, including bacteria, viruses and fungi and is typically used in hospitals and homes.
About TIDREC
TIDREC serves as a focal point for national and international collaborative research for academic institutions and research industries in Malaysia. TIDREC also emphasizes on education and development of human skills. By advocating safe laboratory science, TIDREC aspires to be an internationally recognized centre of excellence in tropical infectious diseases research and education that serves the health needs of global communities.
TIDREC was the first research centre in the country to install fully certified modular biosafety level 2 & 3 laboratories for research involving highly virulent pathogens. TIDREC is also the only centre currently operating a mock biosafety level 3 training facility. The centre also houses the WHO Collaborating Centre for Arbovirus Reference & Research. The centre offer services such as drug screening, validation test for diagnostic kits and research collaboration on vector-borne diseases.
TIDREC mission is to advance knowledge by focusing on research in neglected tropical infectious diseases that have a potential impact on the global community.
About Mundipharma
Mundipharma’s independent associated companies are privately owned entities covering the world’s pharmaceutical markets. Mundipharma is a prime example of a company that consistently delivers high-quality products while standing by the values that represent the company. Our mission is to alleviate the suffering of patients with cancer and non-cancer pain and to substantially improve their quality of life. Mundipharma is dedicated to bringing to patients with severe and debilitating diseases the benefit of novel treatment options in fields such as pain, oncology, oncology supportive care, ophthalmology, respiratory disease and consumer healthcare.
About BETADINE®
The BETADINE® range of products have been trusted by hospitals and consumers around the world for over 60 years to prevent and treat infections. Over the last few years, Mundipharma has expanded the BETADINE® range of products to include Povidone-iodine and non-povidone iodine ranges for the prevention, treatment and maintenance of a range of conditions from upper respiratory tract infections, wound infections, feminine hygiene and infections and outbreaks to personal and hand hygiene. In-vitro and clinical studies have demonstrated that BETADINE® Povidone-iodine kills a broad range of bacteria, viruses and fungi including antibiotic-resistant strains.
®: BETADINE is a registered trademark of Mundipharma
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200630005731/en/
Contact information
For further information please contact:
Alice George
Principal Consultant
AG Global Communications
A-13-4, Tiara Faber
456, Jalan Desa Utama
Taman Desa
58100 Kuala Lumpur
Malaysia
Email: alice.agcomm@gmail.com
Mobile: +60196008157
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CORRECTING and REPLACING Yamaha to Acquire Disguise, Expanding Its Capabilities in Integrated Audio, Video, Lighting and Media13.11.2026 19:10:00 EET | Press release
Please replace the release issued Nov. 12, 2026, at 11:00 p.m. PT/Nov. 13, 2026, at 2:00 a.m. ET with the following corrected version due to multiple revisions in the third paragraph. This release has been updated to ensure the accuracy of certain references in the original version. The updated release reads: YAMAHA TO ACQUIRE DISGUISE, EXPANDING ITS CAPABILITIES IN INTEGRATED AUDIO, VIDEO, LIGHTING AND MEDIA Acquisition combines Yamaha’s audio expertise with Disguise’s software and media server technologies Yamaha Corporation today announced an agreement to acquire Disguise Technologies Limited (“Disguise”), a London-based provider of software and media server technologies for live and immersive experiences. Yamaha will acquire the company by purchasing all shares in its parent, Butterfly Topco Limited. The acquisition will expand Yamaha’s capabilities beyond audio into integrated audio, video, lighting and media solutions, in line with its strategy to expand beyond hardware into soft
VELOCIFERO Takes Action Against Counterfeiting in China13.11.2026 18:32:00 EET | Press release
VELOCIFERO is taking action against counterfeiting in China. White s.r.o., the exclusive owner of the VELOCIFERO brand and its related intellectual property rights, has launched decisive measures to protect its creative and industrial assets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261113797570/en/ Photo courtesy of White s.r.o. “Vehicle sealed in Chongqing as part of actions undertaken to protect VELOCIFERO’s intellectual property rights.” The matter originated in June 2026 when, according to the company’s complaint, computers were removed from the technical office of Taizhou Siweiluo, the company appointed to manufacture VELOCIFERO products. White s.r.o. subsequently became aware of the promotion and sale of vehicles that it believes were produced in violation of its intellectual property rights. White s.r.o. therefore decided to take direct action in China, entrusting the protection of its rights to Shanghai-based
LangChain Raises $300M to Enable Every Company to Own Their Intelligence13.11.2026 17:53:00 EET | Press release
LangChain today announced it has raised $300 million in new funding at a $3 billion valuation, bringing total funding to date to $460 million. The round was led by existing investor CapitalG, with significant participation from new investors GIC and DFJ Growth and existing investors IVP and Sapphire Ventures. LangChain is advancing its mission to help every company own its intelligence. As agents transform the economy, companies are building domain-specific agents differentiated by their knowledge, data, and user experience. These agents will power new products and transform internal company operations, creating lasting competitive advantages for the companies that control them. "Agents are going to transform how companies operate and the products they deliver. The companies that control these systems will build lasting competitive advantages," said Harrison Chase, Co-Founder and CEO of LangChain. "Every company should be free to choose the best models for its needs, control its data a
Kinaxis Named a Leader in Five 2026 IDC MarketScapes for Worldwide Supply Chain Planning13.11.2026 14:00:00 EET | Press release
Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain planning and orchestration, today announced it has been named a Leader in five 2026 IDC MarketScape vendor assessments for worldwide supply chain planning. The recognition spans the overall market and four industries - discrete industries, process industries, consumer packaged goods and life sciences industries - all served by a single platform, Kinaxis Maestro®, the company's AI-powered supply chain orchestration platform. "Supply chain leaders don't need a better forecast once a month. They need to know what changed this morning, what it means across the business, and what to do about it," said Andrew Bell, Chief Product Officer of Kinaxis. "I believe being named a Leader across five IDC MarketScape vendor assessments, in industries that plan in very different ways, shows that a single concurrent platform is the right foundation for that. Operational orchestration builds on it by connecting planning, decisions and ex
SBC Medical Announces Capital and Business Alliance with NeuroBrain Dynamics to Advance Clinic Profitability Through Medical AI13.11.2026 13:30:00 EET | Press release
SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“The Company” or “SBC Medical”), a Medical Services Organization (MSO) providing management support across a wide range of healthcare fields, today announced a strategic capital and business alliance agreement with NeuroBrain Dynamics Inc. (“NBD”), a Taipei-based company dedicated to enterprise generative AI solutions. As part of the agreement executed on November 13, 2026, SBC Medical has made a minority equity investment in NBD. Through this alliance, SBC Medical plans to introduce two complementary suites of generative AI solutions across its network of 287 clinics in Japan and overseas*: “revenue-growth AI,” to elevate average revenue per visit and customer retention through personalized customer guidance, and “cost-reduction AI,” to streamline medical documentation, staff scheduling, and promotional workflows. These initiatives are designed to improve per-clinic profitability. Furthermore, SBC Medical has secured priority sale
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
